XRAY Form 4: Jonathan Mazelsky awarded 2,386 phantom stock units

Rhea-AI Filing Summary

Jonathan Jay Mazelsky, a director of DENTSPLY SIRONA Inc. (XRAY), was granted phantom stock units on 09/30/2025. The Form 4 reports an award of 2,386.165 phantom stock units under the directors' deferred compensation plan, with an indicated price of $12.57 per underlying share. Each phantom share is the economic equivalent of one share of common stock and becomes payable in common stock upon the reporting persons termination of service. After the reported award, the Form shows 11,620.2024 shares beneficially owned by the reporting person in a direct ownership form.

Positive

• Director received 2,386.165 phantom stock units under the directors' deferred compensation plan
• Phantom units are payable in common stock, making the economic exposure equivalent to shares

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received a routine phantom stock award of 2,386.165 units, increasing direct beneficial ownership to 11,620.2024 shares.

The Form 4 documents a non-derivative economic award in the form of phantom stock under the directors' deferred compensation arrangement. The units are described as the economic equivalent of common shares and are payable in common stock upon termination of service. The report lists a per-share price of $12.57 associated with the underlying common stock for this grant and shows the transaction dated 09/30/2025.

Corporate Governance Expert

TL;DR: This is a standard director deferred-compensation grant; disclosure complies with Section 16 reporting requirements.

The filing indicates the directors compensation was awarded as phantom stock units that convert to common shares upon termination. The disclosure includes the necessary elements: transaction date, number of units, price reference, and beneficial ownership after the award. No amendments or joint filers are indicated and the filing was signed by an attorney-in-fact on 10/01/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

MAZELSKY JONATHAN JAY

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NC 28277

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock (Directors' Deferred Compensation) DDC	(1)	09/30/2025		A		2,386.165(2)		(1)	(1)	Common Stock	2,386.165	$12.57	11,620.2024	D

Explanation of Responses:

1. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director.

2. Comprised of phantom stock.

	/s/ Jessica Causey, Attorney-in-Fact for Jonathan Jay Mazelsky	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 for XRAY report on 09/30/2025?

The Form 4 reports a grant of 2,386.165 phantom stock units to director Jonathan Jay Mazelsky dated 09/30/2025.

How many shares does Jonathan Jay Mazelsky beneficially own after the transaction?

The filing shows 11,620.2024 shares beneficially owned following the reported transaction, held in a direct form.

What is the economic nature of the phantom stock?

Each phantom stock unit is described as the economic equivalent of one share of common stock and becomes payable in common stock upon the directors termination of service.

What price is listed for the underlying shares in the Form 4?

The Form 4 lists a price of $12.57 associated with the underlying common stock for this grant.

Who signed the Form 4 and when was it filed?

The Form 4 is executed by Jessica Causey, Attorney-in-Fact for Jonathan Jay Mazelsky with an execution date of 10/01/2025 and the transaction date of 09/30/2025.